740 related articles for article (PubMed ID: 15916743)
1. Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines.
Yang FG; Zhang ZW; Xin DQ; Shi CJ; Wu JP; Guo YL; Guan YF
Acta Pharmacol Sin; 2005 Jun; 26(6):753-61. PubMed ID: 15916743
[TBL] [Abstract][Full Text] [Related]
2. Induction of G1 phase arrest and apoptosis in MDA-MB-231 breast cancer cells by troglitazone, a synthetic peroxisome proliferator-activated receptor gamma (PPARgamma) ligand.
Yu HN; Lee YR; Noh EM; Lee KS; Kim JS; Song EK; Han MK; Lee YC; Kwon KB; Lee SJ; Youn HJ; Jung SH
Cell Biol Int; 2008 Aug; 32(8):906-12. PubMed ID: 18474441
[TBL] [Abstract][Full Text] [Related]
3. Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer.
Lin MS; Chen WC; Bai X; Wang YD
J Dig Dis; 2007 May; 8(2):82-8. PubMed ID: 17532820
[TBL] [Abstract][Full Text] [Related]
4. Ligands for peroxisome proliferator-activated receptor gamma have potent antitumor effect against human renal cell carcinoma.
Yuan J; Takahashi A; Masumori N; Uchida K; Hisasue S; Kitamura H; Itoh N; Tsukamoto T
Urology; 2005 Mar; 65(3):594-9. PubMed ID: 15780399
[TBL] [Abstract][Full Text] [Related]
5. Peroxisome proliferator-activated receptor gamma ligand troglitazone induces cell cycle arrest and apoptosis of hepatocellular carcinoma cell lines.
Yoshizawa K; Cioca DP; Kawa S; Tanaka E; Kiyosawa K
Cancer; 2002 Nov; 95(10):2243-51. PubMed ID: 12412180
[TBL] [Abstract][Full Text] [Related]
6. The ligands of peroxisome proliferator-activated receptor (PPAR) gamma inhibit growth of human esophageal carcinoma cells through induction of apoptosis and cell cycle arrest.
Fujii D; Yoshida K; Tanabe K; Hihara J; Toge T
Anticancer Res; 2004; 24(3a):1409-16. PubMed ID: 15274302
[TBL] [Abstract][Full Text] [Related]
7. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo.
Yu J; Qiao L; Zimmermann L; Ebert MP; Zhang H; Lin W; Röcken C; Malfertheiner P; Farrell GC
Hepatology; 2006 Jan; 43(1):134-43. PubMed ID: 16374840
[TBL] [Abstract][Full Text] [Related]
8. Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human. Pancreatic carcinoma cells.
Motomura W; Okumura T; Takahashi N; Obara T; Kohgo Y
Cancer Res; 2000 Oct; 60(19):5558-64. PubMed ID: 11034103
[TBL] [Abstract][Full Text] [Related]
9. Relationship between peroxisome proliferator-activated receptor-gamma expression and differentiation of human esophageal squamous cell carcinoma.
Takashima T; Fujiwara Y; Hamaguchi M; Sasaki E; Tominaga K; Watanabe T; Oshitani N; Higuchi K; Arakawa T
Oncol Rep; 2005 Apr; 13(4):601-6. PubMed ID: 15756430
[TBL] [Abstract][Full Text] [Related]
10. Activation of peroxisome proliferator-activated receptor-gamma by troglitazone (TGZ) inhibits human lung cell growth.
Li M; Lee TW; Mok TS; Warner TD; Yim AP; Chen GG
J Cell Biochem; 2005 Nov; 96(4):760-74. PubMed ID: 16149072
[TBL] [Abstract][Full Text] [Related]
11. Peroxisome proliferator-activated receptor-gamma ligands inhibit proliferation and induce apoptosis in mantle cell lymphoma.
Eucker J; Sterz J; Krebbel H; Zavrski I; Kaiser M; Zang C; Heider U; Jakob C; Elstner E; Sezer O
Anticancer Drugs; 2006 Aug; 17(7):763-9. PubMed ID: 16926626
[TBL] [Abstract][Full Text] [Related]
12. Troglitazone inhibits cell growth and induces apoptosis of B-cell acute lymphoblastic leukemia cells with t(14;18).
Takenokuchi M; Saigo K; Nakamachi Y; Kawano S; Hashimoto M; Fujioka T; Koizumi T; Tatsumi E; Kumagai S
Acta Haematol; 2006; 116(1):30-40. PubMed ID: 16809887
[TBL] [Abstract][Full Text] [Related]
13. The effect of peroxisome proliferator-activated receptor-gamma ligand on urological cancer cells.
Yoshimura R; Matsuyama M; Hase T; Tsuchida K; Kuratsukuri K; Kawahito Y; Sano H; Segawa Y; Nakatani T
Int J Mol Med; 2003 Dec; 12(6):861-5. PubMed ID: 14612958
[TBL] [Abstract][Full Text] [Related]
14. The peroxisome proliferator-activated receptor gamma ligands, pioglitazone and 15-deoxy-Delta(12,14)-prostaglandin J(2), have antineoplastic effects against hepatitis B virus-associated hepatocellular carcinoma cells.
Shim J; Kim BH; Kim YI; Kim KY; Hwangbo Y; Jang JY; Dong SH; Kim HJ; Chang YW; Chang R
Int J Oncol; 2010 Jan; 36(1):223-31. PubMed ID: 19956851
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of cyclooxygenase-2 expression and activation of caspase-3 are involved in peroxisome proliferator-activated receptor-gamma agonists induced apoptosis in human monocyte leukemia cells in vitro.
Liu JJ; Liu PQ; Lin DJ; Xiao RZ; Huang M; Li XD; He Y; Huang RW
Ann Hematol; 2007 Mar; 86(3):173-83. PubMed ID: 17089125
[TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptor gamma is frequently underexpressed in renal cell carcinoma.
Yuan J; Takahashi A; Masumori N; Itoh N; Tsukamoto T
Int J Urol; 2006 Mar; 13(3):265-70. PubMed ID: 16643621
[TBL] [Abstract][Full Text] [Related]
17. A novel PPAR alpha/gamma dual agonist inhibits cell growth and induces apoptosis in human glioblastoma T98G cells.
Liu DC; Zang CB; Liu HY; Possinger K; Fan SG; Elstner E
Acta Pharmacol Sin; 2004 Oct; 25(10):1312-9. PubMed ID: 15456533
[TBL] [Abstract][Full Text] [Related]
18. Effects of curcumin on peroxisome proliferator-activated receptor gamma expression and nuclear translocation/redistribution in culture-activated rat hepatic stellate cells.
Cheng Y; Ping J; Xu LM
Chin Med J (Engl); 2007 May; 120(9):794-801. PubMed ID: 17531121
[TBL] [Abstract][Full Text] [Related]
19. Induction mechanism of apoptosis by troglitazone through peroxisome proliferator-activated receptor-gamma in gastric carcinoma cells.
Yoshida K; Tanabe K; Fujii D; Oue N; Yasui W; Toge T
Anticancer Res; 2003; 23(1A):267-73. PubMed ID: 12680223
[TBL] [Abstract][Full Text] [Related]
20. Ligands for the peroxisome proliferator-activated receptor-gamma have inhibitory effects on growth of human neuroblastoma cells in vitro.
Valentiner U; Carlsson M; Erttmann R; Hildebrandt H; Schumacher U
Toxicology; 2005 Sep; 213(1-2):157-68. PubMed ID: 16009482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]